During each phase of the study, including the run-in period, patients recorded the following on diary cards:
1. Symptom scores of cough and dyspnea during the preceding 12 h (twice daily recordings). Cough was scored as follows: (a) no cough, (b) occasional cough, (c) bad cough— intermittently, (d) bad cough most of the time. Dyspnea was scored as follows: (a) did not wake up at night, (b) awoke one to three times but slept between, (c) awoke four to six times but slept between, (d) awoke more than six times.
2. Inhaler use over the preceding 12 h (twice daily).
3. Morning and evening peak flow measurements. Each patient was trained to use a mini-Wright peak flow meter and to record each of three attempts.
4. Time of daily medication intake. canadian neighbor pharmacy com
These data served as an indication of the chronic day-to-day control of asthma throughout the 12-week study.
Adverse effects volunteered by patients were recorded. Study medications were returned at each visit and checked to confirm compliance.
Data were analyzed using paired f-tests with the Bonferroni correction for multiple comparisons. Since one of the hypotheses we were testing was the hypotensive effect of these agents, any possible hypertensive effect was not considered, so that singletailed f-tests were used. Probability values less than 0.05 were considered significant.
Of the 12 patients initially entered, two were withdrawn. The first patient (No. 4, Table 1) was withdrawn because of severe bronchospasm associated with an upper respiratory tract infection during the placebo run-in phase, and the second patient (No. 10, Table 1) was withdrawn at the end of the first celiprolol treatment phase because of an unacceptable blood pressure rise requiring a change in therapy. However, the second patient was a severe hypertensive who had untreated blood pressure of 210/150 mm Hg, and therefore was actually incorrectly entered into the trial. The data from both patients were excluded from the analysis, since they had not completed active therapy.